Literature DB >> 20413678

Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes.

Ji Eun Oh1, Hee Sun Lim, Chang Hyeok An, Eun Goo Jeong, Ji Youn Han, Sug Hyung Lee, Nam Jin Yoo.   

Abstract

Detection of somatic mutations in clinical cancer specimens is often hampered by excess wild-type DNA. The aim of this study was to develop a simple and economical protocol without using fluorescent probes to detect low-level mutations. In this study, we combined peptide nucleic acid (PNA)-clamping PCR with asymmetric primers and a melting curve analysis using an unlabeled detection probe. PNA-clamping PCR, which suppressed amplification of the wild-type allele, was more sensitive for KRAS codon 12 mutation detection than nonclamping PCR in 5 different mutant cell lines. Three detection probes were tested (a perfectly matched antisense, a mismatched antisense, and a mismatched sense), and the mismatched sense detection probe showed the highest sensitivity (0.1% mutant detection) under clamping conditions. With this probe, we were able to detect not only the perfectly matched KRAS mutation, but also 4 other mismatched mutations of KRAS. We then applied this protocol to 10 human colon cancer tissues with KRAS codon 12 mutations, successfully detecting the mutations in all of them. Our data indicate that the combination of perfectly matched antisense PNA and a mismatched sense detection probe can detect KRAS mutations with a high sensitivity in both cell lines and human tissues. Moreover, this study might prove an easily applicable protocol for the detection of low-level mutations in other cancer genes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413678      PMCID: PMC2893625          DOI: 10.2353/jmoldx.2010.090146

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  26 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 2.  Genotypic selection methods for the direct analysis of point mutations.

Authors:  B L Parsons; R H Heflich
Journal:  Mutat Res       Date:  1997-10       Impact factor: 2.433

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

4.  Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.

Authors:  S H Lee; M S Shin; W S Park; S Y Kim; H S Kim; J Y Han; G S Park; S M Dong; J H Pi; C S Kim; S H Kim; J Y Lee; N J Yoo
Journal:  Oncogene       Date:  1999-06-24       Impact factor: 9.867

5.  A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia.

Authors:  D R Jacobson; N E Mills
Journal:  Oncogene       Date:  1994-02       Impact factor: 9.867

6.  Single base pair mutation analysis by PNA directed PCR clamping.

Authors:  H Orum; P E Nielsen; M Egholm; R H Berg; O Buchardt; C Stanley
Journal:  Nucleic Acids Res       Date:  1993-11-25       Impact factor: 16.971

7.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

8.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

9.  K-ras mutations and HLA-DR expression in large bowel adenomas.

Authors:  S Norheim Andersen; J Breivik; T Løvig; G I Meling; G Gaudernack; O P Clausen; A Schjölberg; O Fausa; F Langmark; E Lund; T O Rognum
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

10.  Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes.

Authors:  J Däbritz; J Hänfler; R Preston; J Stieler; H Oettle
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  16 in total

1.  Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.

Authors:  Jung Ha Shin; Youn Soo Lee; Yong-Kil Hong; Chang Suk Kang
Journal:  J Neurooncol       Date:  2013-10-16       Impact factor: 4.130

Review 2.  Integrating liquid biopsies into the management of cancer.

Authors:  Giulia Siravegna; Silvia Marsoni; Salvatore Siena; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2017-03-02       Impact factor: 66.675

Review 3.  KRAS mutation testing in metastatic colorectal cancer.

Authors:  Cong Tan; Xiang Du
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

4.  Stress-induced DNA damage: a case study in diffuse large B-cell lymphoma.

Authors:  Luz Adriana Nicasio-Collazo; Alexandra Delgado-González; Ramón Castañeda-Priego; Enrique Hernández-Lemus
Journal:  J R Soc Interface       Date:  2014-11-06       Impact factor: 4.118

5.  COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma.

Authors:  Colin C Pritchard; Laura Akagi; Poluru L Reddy; Loren Joseph; Jonathan F Tait
Journal:  BMC Clin Pathol       Date:  2010-11-26

6.  Eprobe-mediated screening system for somatic mutations in the KRAS locus.

Authors:  Jun Atsumi; Takeshi Hanami; Yasuaki Enokida; Hiroomi Ogawa; Diane Delobel; Yasumasa Mitani; Yasumasa Kimura; Takahiro Soma; Michihira Tagami; Yoshiaki Takase; Tatsuo Ichihara; Izumi Takeyoshi; Kengo Usui; Yoshihide Hayashizaki; Kimihiro Shimizu
Journal:  Oncol Rep       Date:  2015-03-30       Impact factor: 3.906

7.  Real-time bidirectional pyrophosphorolysis-activated polymerization for quantitative detection of somatic mutations.

Authors:  Najie Song; Xueting Zhong; Qingge Li
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

8.  Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.

Authors:  Jun-Fu Huang; Dong-Zhu Zeng; Guang-Jie Duan; Yan Shi; Guo-Hong Deng; Han Xia; Han-Qing Xu; Na Zhao; Wei-Ling Fu; Qing Huang
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

9.  Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Authors:  Hélène Blons; Etienne Rouleau; Nathanaël Charrier; Gilles Chatellier; Jean-François Côté; Jean-Christophe Pages; Florence de Fraipont; Jean-Christophe Boyer; Jean Philippe Merlio; Alain Morel; Marie-Claude Gorisse; Patricia de Cremoux; Karen Leroy; Gérard Milano; L'houcine Ouafik; Jean-Louis Merlin; Delphine Le Corre; Pascaline Aucouturier; Jean-Christophe Sabourin; Frédérique Nowak; Thierry Frebourg; Jean-François Emile; Isabelle Durand-Zaleski; Pierre Laurent-Puig
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

Review 10.  Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.

Authors:  Manuel Caitano Maia; Meghan Salgia; Sumanta K Pal
Journal:  Nat Rev Urol       Date:  2020-03-17       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.